Abiopharma

🔍 Guyer William (Executive)

Company: CORCEPT THERAPEUTICS INC (CORT)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 11,767 shares of Common Stock at $21.65 per share (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: false | shares_owned_after: 13,998.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,767 shares of Common Stock at $36.01 per share (Direct)
  Date: 2026-03-20 | Code: S | equity_swap_involved: false | shares_owned_after: 2,231.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
• Sold 11,767 shares of Stock Option (right to buy) at $21.65 per share (Derivative)
  Date: 2026-03-20 | Code: M | Expires: 2031-09-01 | equity_swap_involved: false | shares_owned_after: 210,000.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
• F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
• F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F4: Fully exercisable.
• REMARKS: The power of attorney under which this form was signed is on file with the Commission.